Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 187

Similar articles for PubMed (Select 17429106)


Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells.

Bertagnolo V, Benedusi M, Brugnoli F, Lanuti P, Marchisio M, Querzoli P, Capitani S.

Carcinogenesis. 2007 Aug;28(8):1638-45. Epub 2007 Apr 11.


PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays.

Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F, Capitani S.

Int J Oncol. 2006 Apr;28(4):863-72.


A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.

Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A.

Clin Cancer Res. 1999 Aug;5(8):2251-60.


PLC-beta2 activity on actin-associated polyphosphoinositides promotes migration of differentiating tumoral myeloid precursors.

Brugnoli F, Bavelloni A, Benedusi M, Capitani S, Bertagnolo V.

Cell Signal. 2007 Aug;19(8):1701-12. Epub 2007 Mar 28.


Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.

Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, Jansen MK, Csiszar K, Hendrix MJ, Kirschmann DA.

J Cell Biochem. 2008 Apr 1;103(5):1369-78.


CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.


Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.

Liu S, Goldstein RH, Scepansky EM, Rosenblatt M.

Cancer Res. 2009 Nov 15;69(22):8742-51. doi: 10.1158/0008-5472.CAN-09-1541. Epub 2009 Nov 3.


Molecular inhibition of phospholipase cgamma signaling abrogates DU-145 prostate tumor cell invasion.

Turner T, Epps-Fung MV, Kassis J, Wells A.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2275-82.


Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human colon carcinomas and colon carcinoma cell lines.

Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR, Weinstein IB.

Mol Carcinog. 1995 Mar;12(3):146-52.


Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction.

Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelista C, Bortul R, Follo MY, Falà F, Cocco L.

Histol Histopathol. 2005 Oct;20(4):1251-60. Review.


Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells.

Abalsamo L, Spadaro F, Bozzuto G, Paris L, Cecchetti S, Lugini L, Iorio E, Molinari A, Ramoni C, Podo F.

Breast Cancer Res. 2012 Mar 19;14(2):R50.


In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness.

Brugnoli F, Grassilli S, Piazzi M, Palomba M, Nika E, Bavelloni A, Capitani S, Bertagnolo V.

Mol Cancer. 2013 Dec 13;12:165. doi: 10.1186/1476-4598-12-165.


Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS.

Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.


Nuclear but not cytoplasmic phospholipase C beta 1 inhibits differentiation of erythroleukemia cells.

Matteucci A, Faenza I, Gilmour RS, Manzoli L, Billi AM, Peruzzi D, Bavelloni A, Rhee SG, Cocco L.

Cancer Res. 1998 Nov 15;58(22):5057-60.


Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.

Privette LM, González ME, Ding L, Kleer CG, Petty EM.

Cancer Res. 2007 Jul 1;67(13):6064-74. Epub 2007 Jun 27.


Stable association between G alpha(q) and phospholipase C beta 1 in living cells.

Dowal L, Provitera P, Scarlata S.

J Biol Chem. 2006 Aug 18;281(33):23999-4014. Epub 2006 Jun 5.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk